Portfolio (2)

Les photos de ce portfolio ont été prises par  Philippe Carta, Julien Goetz, Francis Guermann, Bernard Muscat et Michel Noirez. (Tous droits réservés) Projecteur et enrouleur 35 mm mobiles installés dans le vestibule de l’Opéra-Théâtre pour la projection de Moïse et Aaron – 24 mars 2011. Avant la projection de Moïse et Aaron, Jean-Marie Straub, debout face à l’écran de l’Opéra-Théâtre, vérifie la qualité de l’image et du son. François Narboni et Régine Palucci présentent Moïse et Aaron. A..

New approach of delivering cytotoxic drugs towards CAIX expressing cells : A concept of dual-target drugs

Abstract Carbonic anhydrase IX (CAIX) is a hypoxia-regulated and tumor-specific protein that maintains the pH balance of cells. Targeting CAIX might be a valuable approach for specific delivery of cytotoxic drugs, thereby reducing normal tissue side-effects. A series of dual-target compounds were designed and synthesized incorporating a sulfonamide, sulfamide, or sulfamate moiety combined with several different anti-cancer drugs, including the chemotherapeutic agents chlorambucil, tirapazamine, and temozolomide, two Ataxia Telangiectasia and Rad3-related protein inhibitors (ATRi), and the anti-diabetic biguanide agent phenformin. An ATRi derivative (12) was the only compound to show a preferred efficacy in CAIX overexpressing cells versus cells without CAIX expression when combined with radiation. Its efficacy might however not solely depend on binding to CAIX, since all described compounds generally display low activity as carbonic anhydrase inhibitors. The hypothesis that dual-target compounds specifically target CAIX expressing tumor cells was therefore not confirmed. Even though dual-target compounds remain an interesting approach, alternative options should also be investigated as novel treatment strategies

Monoaminergic and histaminergic strategies and treatments in brain diseases

The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from in vivo neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable strategies for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson's disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer's disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review.peer-reviewe

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon

Endoscopy skull-base resection for ethmoid adenocarcinoma and olfactory neuroblastoma

Olfactory neuroblastoma (ON) and ethmoid adenocarcinoma (AC) are rare sinonasal malignancies that often involve the skull base. Standard surgical treatment is craniofacial resection (CFR), which allows for efficient removal but entails significant morbidity and mortality. Because expanded endoscopy nasal approaches are newly developed, we aimed to describe the procedure in patients with ON and AC and compare it with CFR in terms of efficiency and morbidity

Portfolio (1)

Les photos de ce portfolio ont été prises par  Philippe Carta, Julien Goetz, Francis Guermann, Bernard Muscat et Michel Noirez. (Tous droits réservés) Jean-Marie Straub, chez lui, à Paris – 9 janvier 2011. Inauguration de la rétrospective Straub-Huillet : René Cahen (Ligue de l’enseignement), Régine Palucci (Ciné Art), Laurent Le Bon (Directeur du Centre Pompidou-Metz), Antoine Fonte (Adjoint à la Culture de la ville de Metz) et Jean-Marie Straub -Centre Pompidou-Metz – 11 mars 2011. Antoi..

UVSQ-SAT, a small nanosatellite to observe the Sun and the Earth - Imagine a new way for measuring Earth's energy imbalance

International audienceUVSQ-SAT (UV & IR Sensors at high Quantum efficiency onboard a small SATellite) is a small nanosatellite (10 cm × 10 cm × 11.35 cm, 1.4 kg, 1.6 W), which is scheduled to be launched in December 2020 on a low Earth orbit with an altitude between 500 and 600 km. The objectives of this in-orbit demonstration CubeSat range from science to education and outreach. The first scientific goal is to measure the incoming solar radiations (total solar irradiance) and the outgoing terrestrial radiations (top of atmosphere outgoing longwave radiations and shortwave radiations) using twelve miniaturized thermopiles sensors. The second scientific goal is to monitor the solar spectral irradiance at 215 nm (Herzberg solar continuum) using four photodiodes based on intrinsic advantages of pulsed laser deposition of ZnO nanostructures with MgZnO alloy. The third objective is to space-qualified a medical device for astronauts. All UVSQ-SAT instruments can acquire the technical maturity for the future large missions (constellation that insure global measurement cover) by flying in a CubeSat. The UVSQ-SAT mission is intended to demonstrate the ability to build a low-cost satellite with a high accuracy measurement in order to have constant flow of data from space by using miniaturized instruments (volume, mass, power, telemetry)